[go: up one dir, main page]

WO2012034065A1 - Intermédiaires d'aliskirène et procédé destiné à analyser la pureté de l'aliskirène - Google Patents

Intermédiaires d'aliskirène et procédé destiné à analyser la pureté de l'aliskirène Download PDF

Info

Publication number
WO2012034065A1
WO2012034065A1 PCT/US2011/051076 US2011051076W WO2012034065A1 WO 2012034065 A1 WO2012034065 A1 WO 2012034065A1 US 2011051076 W US2011051076 W US 2011051076W WO 2012034065 A1 WO2012034065 A1 WO 2012034065A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
group
imp
aliskiren
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/051076
Other languages
English (en)
Inventor
Marina Etinger
Meital Sharabi
Ariel Mittelman
Yifat Ronen
Keren Wiess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Publication of WO2012034065A1 publication Critical patent/WO2012034065A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups

Definitions

  • Figure 10 provides a H NMR spectrum of compound IX.
  • a crystal form may be referred to herein as being characterized by graphical data "as depicted in" a Figure.
  • Such data include, for example, powder X-ray diffracto- grams, FTIR spectra, and solid state NMR spectra.
  • the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to factors such as variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figures herein with graphical data generated for an unknown crystal form and confirming whether the two sets of graphical data are characterizing the same crystal form or two different crystal forms.
  • Compound DC can be in amorphous or crystalline form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Cette invention concerne des impuretés et des intermédiaires d'aliskirène, et des procédés pour les préparer. Cette invention concerne également des procédés de préparation d'aliskirène à l'aide de ces intermédiaires et de ces impuretés. Ces impuretés peuvent également être utilisées comme marqueurs ou étalons de référence pour déterminer la pureté de l'aliskirène ou de ses intermédiaires.
PCT/US2011/051076 2010-09-09 2011-09-09 Intermédiaires d'aliskirène et procédé destiné à analyser la pureté de l'aliskirène Ceased WO2012034065A1 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US38133710P 2010-09-09 2010-09-09
US61/381,337 2010-09-09
US41406110P 2010-11-16 2010-11-16
US61/414,061 2010-11-16
US41997610P 2010-12-06 2010-12-06
US61/419,976 2010-12-06
US201161467126P 2011-03-24 2011-03-24
US61/467,126 2011-03-24
US201161474040P 2011-04-11 2011-04-11
US61/474,040 2011-04-11

Publications (1)

Publication Number Publication Date
WO2012034065A1 true WO2012034065A1 (fr) 2012-03-15

Family

ID=44678048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/051076 Ceased WO2012034065A1 (fr) 2010-09-09 2011-09-09 Intermédiaires d'aliskirène et procédé destiné à analyser la pureté de l'aliskirène

Country Status (1)

Country Link
WO (1) WO2012034065A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294612A (zh) * 2014-06-05 2016-02-03 山东威智医药工业有限公司 阿利克仑中间体及其制备方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559111A (en) 1994-04-18 1996-09-24 Ciba-Geigy Corporation δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
US6333198B1 (en) 1998-06-10 2001-12-25 Glaxo Wellcome, Inc. Compound and its use
WO2002008172A1 (fr) * 2000-07-25 2002-01-31 Speedel Pharma Ag Procede de fabrication d'octanoylamides substitues
WO2003103653A1 (fr) * 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methodes de traitement de la maladie d'alzheimer par des amides d'acide aryl alcanoique
US20080234945A1 (en) * 2005-07-25 2008-09-25 Metanomics Gmbh Means and Methods for Analyzing a Sample by Means of Chromatography-Mass Spectrometry
WO2009064479A1 (fr) 2007-11-13 2009-05-22 Teva Pharmaceutical Industries Ltd. Formes polymorphes de l'hémifumarate d'aliskiren et procédé pour la préparation de celles-ci

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559111A (en) 1994-04-18 1996-09-24 Ciba-Geigy Corporation δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
US6333198B1 (en) 1998-06-10 2001-12-25 Glaxo Wellcome, Inc. Compound and its use
WO2002008172A1 (fr) * 2000-07-25 2002-01-31 Speedel Pharma Ag Procede de fabrication d'octanoylamides substitues
WO2003103653A1 (fr) * 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methodes de traitement de la maladie d'alzheimer par des amides d'acide aryl alcanoique
US20080234945A1 (en) * 2005-07-25 2008-09-25 Metanomics Gmbh Means and Methods for Analyzing a Sample by Means of Chromatography-Mass Spectrometry
WO2009064479A1 (fr) 2007-11-13 2009-05-22 Teva Pharmaceutical Industries Ltd. Formes polymorphes de l'hémifumarate d'aliskiren et procédé pour la préparation de celles-ci

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DRUGS OF THE FUTURE, vol. 26, no. 12, 2001, pages 1139 - 1148
LINDSAY, K. B. ET AL., J. ORG. CHEM., vol. 71, 2006, pages 4766 - 4777
SNYDER, L.R. ET AL.: "Introduction to Modern Liquid Chromatography", vol. 549, 1979, JOHN WILEY & SONS
STROBEL, H.A. ET AL.: "Chemical Instrumentation: A Systematic Approach", vol. 953, 1989, WILEY & SONS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294612A (zh) * 2014-06-05 2016-02-03 山东威智医药工业有限公司 阿利克仑中间体及其制备方法和应用

Similar Documents

Publication Publication Date Title
CA2934537C (fr) Synthese d'un compose antiviral
US20140316154A1 (en) Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
NO332637B1 (no) Anvendelse av R-(+)-2-(3-diisopropylamino-1-fenylpropyl)-4-hydroksymetyl-fenylisosmørsyreester- hydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer og farmasøytisk formulering derav
AU2200199A (en) Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
US20140275590A1 (en) Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
EP3169692A1 (fr) Nouvelle forme de sofosbuvir et sa méthode de préparation
US20120116074A1 (en) Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid and precursors thereof
IL298316A (en) Process of preparing butyl-(5s)-5-({2-[4-(butoxycarbonyl)phenyl]ethyl}[2-(2-{[3-chloro-4'-(trifluoromethyl)[biphenyl]-4-yl]methoxy}phenyl)ethyl]amino)-5,6,7,8-tetrahydroquinoline-2-carboxylate
EP3103794A1 (fr) Procédé de production d'un composé indoline
WO2012034065A1 (fr) Intermédiaires d'aliskirène et procédé destiné à analyser la pureté de l'aliskirène
WO2009046309A2 (fr) Prégabaline-4-éliminée, prégabaline-5-éliminée, leur utilisation en tant que marqueur de référence et standard et procédé de production de prégabaline contenant de faibles taux de ceux-ci
AU2019347545B2 (en) Novel method for preparing (-)-Cibenzoline succinate
CN109422798B (zh) 一种苯基丙酰胺类衍生物的游离碱晶型及其制备方法
CN100443466C (zh) 环烷基氨基酸化合物及其制备方法和用途
CA2034673A1 (fr) Derive de la 1-pheylalkyl-3-phenyluree
WO2015022702A2 (fr) Procédé de préparation de dérivés de 4,5-diméthoxybenzène et utilisation dans la synthèse de l'ivabradine et de ses sels
US12012424B2 (en) Process for preparation of bis-choline tetrathiomolybdate
US20110124903A1 (en) Solid state forms of fesoterodine intermediates
Avenoza et al. New syntheses of enantiopure 2-methyl isoserines
JP7444363B2 (ja) ２－（２－オキソ－４－置換ピペラジニル）シクロアルキルカルバメート化合物又はその塩、当該化合物を用いる鏡像異性体の分析方法
JP2007509857A (ja) ｛２−［（８，９）−ジオキソ−２，６−ジアザ−ビシクロ［５．２．０］−ノン−１（７）−エン−２−イル］エチル｝ホスホン酸およびそのエステルの調製方法。
EP2860175B1 (fr) Procédé de préparation d'un composé de 4,4,7-trifluoro-1,2,3,4-tétrahydro-5h-1-benzazépine et intermédiaire de synthèse correspondant
CN114072386A (zh) 制备用于合成艾曲波帕或其盐的关键中间体的改进方法
CN105121417B (zh) 经取代噻唑基乙酸三乙胺盐的结晶型
US20140378699A1 (en) Process for the preparation of fesoterodine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11761200

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11761200

Country of ref document: EP

Kind code of ref document: A1